NeuroSense Therapeutics has filed a U.S. patent application for a combination of ciprofloxacin and celecoxib to treat traumatic brain injury (TBI). This expands the potential applications of their lead asset, PrimeC, beyond its current ALS focus, offering a new long-term growth avenue for the company.
NeuroSense Therapeutics has filed a U.S. patent application for a novel method of treating traumatic brain injury (TBI) using a combination of ciprofloxacin and celecoxib. This is significant because TBI represents a major unmet medical need with no approved disease-modifying therapies. The patent, if granted, would provide protection through 2047, offering a long-term commercial opportunity for NeuroSense's lead asset, PrimeC, beyond its primary focus on ALS. While ALS remains the company's priority, this filing signals a strategic move to broaden PrimeC's commercial potential and build additional long-term value, potentially attracting future collaborations or non-dilutive funding. For traders, this represents a moderate long-term positive catalyst, as it diversifies the company's pipeline and market opportunities, though the immediate impact is limited as it's a patent application, not an approval or clinical trial result.